TY - JOUR
T1 - A Double Prodrug with Improved Membrane Permeability over the Parent Chelator HBED Provides Superior Cytoprotection against Hydrogen Peroxide
AU - Thiele, Nikki A.
AU - Sloan, Kenneth B.
N1 - Publisher Copyright:
© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
PY - 2016
Y1 - 2016
N2 - The clinical use of N,N′-bis(2-hydroxybenzyl)ethylenediamine-N,N′-diacetic acid (HBED) has been hindered by its lack of bioavailability. N,N′-bis(2-boronic pinacol ester benzyl)ethylenediamine-N,N′-diacetic acid methyl, ethyl, and isopropyl esters 7 a–c, respectively, and their dimesylate salts 8 a–c, are double prodrugs that mask the two phenolate and two carboxylate donors of HBED as boronic esters and carboxylate esters, respectively. Their activation by chemical hydrolysis and oxidation, their passive diffusivity, and their cytoprotective capabilities have been investigated here. 8 a–c hydrolyzed in minimum essential medium at 37 °C with half-lives of 0.69, 0.81, and 2.28 h, respectively. The intermediate formed, 9 [N,N′-bis(2-boronic acid benzyl)ethylenediamine-N,N′-diacetic acid], then underwent oxidative deboronation by H2O2to give HBED (k=1.82 m−1min−1). Solubility measurements in mineral oil and in phosphate buffer indicated that 7 a had a better balance between lipid and aqueous solubilities than did HBED. 7 a was also able to passively diffuse across a lipid-like silicone membrane (log flux=−0.36), whereas HBED-HCl was not. 8 c provided better protection to retinal cells than did HBED against a lethal dose of H2O2(84 % vs. 28 % protection, respectively, at 44 μm). These results suggest that the double prodrugs have better membrane permeability than does HBED, and therefore could be therapeutically useful for improving the delivery of HBED.
AB - The clinical use of N,N′-bis(2-hydroxybenzyl)ethylenediamine-N,N′-diacetic acid (HBED) has been hindered by its lack of bioavailability. N,N′-bis(2-boronic pinacol ester benzyl)ethylenediamine-N,N′-diacetic acid methyl, ethyl, and isopropyl esters 7 a–c, respectively, and their dimesylate salts 8 a–c, are double prodrugs that mask the two phenolate and two carboxylate donors of HBED as boronic esters and carboxylate esters, respectively. Their activation by chemical hydrolysis and oxidation, their passive diffusivity, and their cytoprotective capabilities have been investigated here. 8 a–c hydrolyzed in minimum essential medium at 37 °C with half-lives of 0.69, 0.81, and 2.28 h, respectively. The intermediate formed, 9 [N,N′-bis(2-boronic acid benzyl)ethylenediamine-N,N′-diacetic acid], then underwent oxidative deboronation by H2O2to give HBED (k=1.82 m−1min−1). Solubility measurements in mineral oil and in phosphate buffer indicated that 7 a had a better balance between lipid and aqueous solubilities than did HBED. 7 a was also able to passively diffuse across a lipid-like silicone membrane (log flux=−0.36), whereas HBED-HCl was not. 8 c provided better protection to retinal cells than did HBED against a lethal dose of H2O2(84 % vs. 28 % protection, respectively, at 44 μm). These results suggest that the double prodrugs have better membrane permeability than does HBED, and therefore could be therapeutically useful for improving the delivery of HBED.
KW - boronic acids
KW - chelation therapy
KW - hydrogen peroxide
KW - iron
KW - prodrugs
UR - http://www.scopus.com/inward/record.url?scp=84981218716&partnerID=8YFLogxK
U2 - 10.1002/cmdc.201600197
DO - 10.1002/cmdc.201600197
M3 - Article
C2 - 27440560
AN - SCOPUS:84981218716
SN - 1860-7179
SP - 1596
EP - 1599
JO - ChemMedChem
JF - ChemMedChem
ER -